Jusdap-M 1000 Tablet ER is a combination oral antidiabetic medication containing Dapagliflozin 10 mg and Metformin 1000 mg, formulated for extended release to provide sustained glycemic control in patients with type 2 diabetes mellitus. Dapagliflozin, a selective sodium-glucose co-transporter 2 (SGLT2) inhibitor, promotes renal glucose excretion, thereby reducing plasma glucose levels independently of insulin secretion. Metformin, a biguanide, primarily decreases hepatic glucose production and improves insulin sensitivity, enhancing peripheral glucose uptake and utilization. The extended-release formulation ensures gradual drug absorption, minimizing gastrointestinal side effects commonly associated with immediate-release metformin. Jusdap-M 1000 is indicated as an adjunct to diet and exercise to improve glycemic control in adults inadequately controlled on either component alone or when treatment with both agents is appropriate. It is contraindicated in patients with severe renal impairment, metabolic acidosis, or hypersensitivity to its components. Caution is advised in patients with risk factors for volume depletion or genitourinary infections due to dapagliflozin’s mechanism of action. Regular monitoring of renal function, glycemic parameters, and potential adverse effects is recommended during therapy. Jusdap-M 1000 Tablet ER offers a convenient, effective option for optimizing blood glucose management in type 2 diabetes.